Who we help
Insights for patients and healthcare professionals who need them
Patients
Our treatment decision support software applications are medical devices registered throughout Europe. They offer your treating physician a unique form of support in finding the right medication for „your“ cancer — medicine that is effective and has as few side effects as possible.
Read more
Physicians
Make customized therapeutic decisions based on molecular genetics and find safe and effective therapies for your cancer patients – with our treatment decision support applications MH Guide, MH Mendel and MH BRCA.
Read more
Hospitals
Become a precision medicine center of excellence -Integrate our treatment decision support software applications into everyday oncological clinical practice and make your tumor boards even more efficient.
Read more
Labs
Big data analytics for laboratories – use our treatment decision support software applications to systematically and safely perform knowledge-based clinical annotations of NGS data, an added value for your lab and your customers.Read more
Regulators
Go beyond what you can learn from a randomized clinical trial to analyze and predict real-world safety of new molecular entities and approved drugs.
Read more
Pharma & Biotech
Apply enhanced AI on biomedical, real-world, and outside trial data to overturn the failure rate of clinical trials – fore more success with less expenditure. Enrich your trial design based on clinic-molecular signals that predict drug safety and efficacy. Validate biomarkers, combinations and repurposing opportunities.
Read more
Corporate Oncology Program for Employees
(COPE)
COPE is designed to give companies a direct and uncomplicated way to offer our IVD medical devices in personalized cancer diagnostics to the employees who need it.
Read more
Let’s talk about how our technology can work for you
To find out more, you can call our customer care team or help desk or send us an e-mail. We would be delighted to provide you with more information or answer your questions.
